MiMedx Group, Inc. (MDXG)
4.55
+0.03
(+0.66%)
USD |
NASDAQ |
Sep 02, 16:00
4.55
0.00 (0.00%)
Pre-Market: 20:00
MiMedx Group Research and Development Expense (TTM) : 15.38M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.38M |
| March 31, 2026 | 15.91M |
| December 31, 2025 | 15.10M |
| September 30, 2025 | 13.90M |
| June 30, 2025 | 13.12M |
| March 31, 2025 | 12.83M |
| December 31, 2024 | 12.34M |
| September 30, 2024 | 11.20M |
| June 30, 2024 | 11.36M |
| March 31, 2024 | 12.02M |
| December 31, 2023 | 12.66M |
| September 30, 2023 | 15.63M |
| June 30, 2023 | 18.51M |
| March 31, 2023 | 20.35M |
| December 31, 2022 | 22.83M |
| September 30, 2022 | 22.00M |
| June 30, 2022 | 20.42M |
| March 31, 2022 | 18.97M |
| December 31, 2021 | 17.34M |
| September 30, 2021 | 16.20M |
| June 30, 2021 | 15.21M |
| March 31, 2021 | 13.40M |
| December 31, 2020 | 11.72M |
| September 30, 2020 | 11.00M |
| June 30, 2020 | 10.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.89M |
| December 31, 2019 | 11.14M |
| September 30, 2019 | 12.96M |
| June 30, 2019 | 14.23M |
| March 31, 2019 | 15.12M |
| December 31, 2018 | 15.77M |
| September 30, 2018 | 14.70M |
| June 30, 2018 | 16.22M |
| March 31, 2018 | 17.24M |
| December 31, 2017 | 17.90M |
| September 30, 2017 | 17.89M |
| June 30, 2017 | 15.32M |
| March 31, 2017 | 13.74M |
| December 31, 2016 | 12.04M |
| September 30, 2016 | 10.92M |
| June 30, 2016 | 10.19M |
| March 31, 2016 | 9.078M |
| December 31, 2015 | 8.413M |
| September 30, 2015 | 7.918M |
| June 30, 2015 | 7.745M |
| March 31, 2015 | 7.491M |
| December 31, 2014 | 7.05M |
| September 30, 2014 | 6.589M |
| June 30, 2014 | 5.862M |
| March 31, 2014 | 4.987M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 27.45M |
| Perspective Therapeutics, Inc. | 82.13M |
| ABVC BioPharma, Inc. | 0.1148M |
| Enovis Corp. | 124.32M |
| Edwards Lifesciences Corp. | 1.091B |